Optipore sequencing:
Moving whole genome sequencing into clinical practice


Advances in understanding the genomic foundation of disease and the increasing availability of targeted therapies are starting to enable personalized treatments based on an understanding of the molecular changes contributing to an individual patient's disease. The increasing complexity of the genetic information needed to select those targeted treatments is beginning to exceed the capabilities of existing molecular diagnostic platforms and will require whole genome sequencing.  Noblegen Biosciences, launched by leaders in molecular diagnostics, sequencing, and biophysics, is building a sequencing platform that aims to meet the requirements to move whole genome sequencing into routine clinical practice.